RIV Capital Inc.
CNPOF · Other OTC · USD
0,08USD
0,00 (0,00 %)Stand 19. Dez., 20:34
Kennzahlen
- Eröffnung
- 0,07
- Vortag
- 0,08
- Tagesspanne
- 0,07 – 0,08
- 52 Wochen
- 0,0621 – 0,169
- Volumen
- 10.100
- Ø Volumen
- 74.898
- Börsenwert
- 10,96 Mio. $
- KGV
- -0,1
- Gewinn je Aktie (TTM)
- -0,51
- Dividendenrendite
- 0,0 %
- Beta
- 0,6
- Nächste Zahlen
- –
Finanzen
| USD | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Umsatz | 2,4 Mio. | 13,43 Mio. | 10,1 Mio. | 8,13 Mio. | 3,16 Mio. |
| Herstellungskosten | 4,37 Mio. | 53,66 Mio. | 53,63 Mio. | 0 | 0 |
| Bruttogewinn | 2,44 Mio. | −40,23 Mio. | −43,53 Mio. | 4,87 Mio. | 54,78 Mio. |
| Forschung und Entwicklung | 0 | −21 | −9 | 0 | 0 |
| Vertrieb und Verwaltung | 18,32 Mio. | 7,76 Mio. | 6,09 Mio. | 13,02 Mio. | 22,81 Mio. |
| Operatives Ergebnis | −43,99 Mio. | −24,37 Mio. | −41,96 Mio. | 8,03 Mio. | 46,81 Mio. |
| EBITDA | −46,25 Mio. | −61,37 Mio. | −7,22 Mio. | 10,38 Mio. | 72,39 Mio. |
| Nettogewinn | −179,26 Mio. | −42,21 Mio. | −106,01 Mio. | −28,59 Mio. | 2,93 Mio. |
| Gewinn je Aktie (verwässert) | -1,09 | -0,30 | -0,75 | -0,15 | 0,02 |
Bewertung
Letzte 12 Monate
- KGV
- -0,1
- Kurs-Umsatz-Verhältnis
- 4,6
- Kurs-Buchwert-Verhältnis
- 0,1
- PEG
- 0,0
- Bruttomarge
- 101,6 %
- Operative Marge
- −1.835,4 %
- Nettomarge
- −7.479,1 %
- Verschuldungsgrad
- 1,0
- EV/EBITDA
- -0,9
- Eigenkapitalrendite
- −96,0 %
- Kapitalrendite (ROIC)
- −7,4 %
- Free-Cashflow-Rendite
- −254,7 %
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Bruttomarge | 101,6 % | −299,5 % | −431,1 % | 59,9 % | 1.731,0 % |
| Operative Marge | −1.835,4 % | −181,4 % | −415,5 % | 98,8 % | 1.479,1 % |
| Nettomarge | −7.479,1 % | −314,3 % | −1.049,8 % | −351,7 % | 92,7 % |
| KGV | -0,1 | -5,2 | -3,1 | -6,0 | 223,4 |
| Kurs-Umsatz-Verhältnis | 7,2 | 16,5 | 33,1 | 20,9 | 207,6 |
| Kurs-Buchwert-Verhältnis | 0,2 | 0,8 | 1,4 | 0,8 | 2,1 |
| Verschuldungsgrad | 1,0 | 0,3 | 0,0 | 0,0 | 0,0 |
| Liquidität 3. Grades | 83,7 | 83,7 | 5,6 | 13,1 | 14,9 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 50,08 Mio. | −15,95 Mio. | 232,83 Mio. | 137,43 Mio. | 579,32 Mio. |
| EV/EBITDA | -1,1 | 0,3 | -32,2 | 13,2 | 8,0 |
| Eigenkapitalrendite | −164,7 % | −15,9 % | −43,0 % | −13,6 % | 1,0 % |
| Kapitalrendite (ROIC) | −7,4 % | −5,6 % | −17,0 % | 1,8 % | 12,9 % |
| Free-Cashflow-Rendite | −162,0 % | −9,8 % | −1,9 % | −3,2 % | −0,3 % |
Wachstum
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Umsatz | −82,2 % | +33,0 % | +24,2 % | +156,9 % | −95,5 % |
| Bruttogewinn | +106,1 % | +7,6 % | −994,4 % | −91,1 % | −22,5 % |
| Operatives Ergebnis | −80,5 % | +41,9 % | −622,7 % | −82,9 % | −22,5 % |
| Nettogewinn | −324,7 % | +60,2 % | −270,8 % | −1.074,4 % | +6.794,8 % |
| Gewinn je Aktie | −263,3 % | +60,0 % | −400,0 % | −952,3 % | +4.500,0 % |
| Freier Cashflow | −28,4 % | −234,4 % | −20,3 % | −174,0 % | −22.240,3 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Aug. 2024 | Apr. 2024 | März 2024 | Nov. 2023 | Aug. 2023 | Juni 2023 | März 2023 | Nov. 2022 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | -0,06 | -0,04 | -0,36 | -0,07 | -0,07 | -0,15 | -0,06 | -0,82 |
| Abweichung | – | – | – | – | – | – | – | – |
| Umsatz · Tatsächlich | 3,79 Mio. | 2,14 Mio. | 2,12 Mio. | 2,3 Mio. | 1,79 Mio. | 1,69 Mio. | 1,89 Mio. | 1,82 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 20. Sept. 201837:1000
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
ACRDFAcreage Holdings, Inc.0,122+2,52 %
ATBPFAntibe Therapeutics Inc.0,2156−0,19 %
LVCLYLiving Cell Technologies Limited0,0306+24,39 %
LXXGFLexaGene Holdings Inc.0,08060,00 %
MGCLFMGC Pharmaceuticals Limited0,2675+2,88 %
MRVFFNuvo Pharmaceuticals Inc.0,97950,00 %
RWBYFRed White & Bloom Brands Inc.0,0279+1,82 %
TPPRFTop Strike Resources Corp.0,04330,00 %
Über das Unternehmen
RIV Capital Inc., previously known as Canopy Rivers Inc., functions as a venture capital firm. Although it employs a flexible investment strategy, engaging with companies from initial seed stages through to commercial sale, it primarily favors Series A to C funding rounds. The company's core focus is the expanding cannabis industry, specifically targeting promising marijuana enterprises. Its investment interests span numerous sub-sectors within the cannabis ecosystem, including agriculture and food sciences, production, processing, pharmaceuticals and biotechnology, software and data, hardware, consumer products and accessories, wellness products, retail and distribution, as well as media and content. The firm also allocates capital to specific product categories such as beverages, capsules and concentrates, edibles, dry flower/pre-rolls, vaporizers and hardware, pet products, and topical applications. Within agriculture and food sciences, RIV Capital supports advancements in plant, soil, food, animal, and environmental sciences. Its production investments encompass various cultivation methods like indoor, greenhouse, outdoor, and nursery cultivation, along with fermentation. In processing, the firm backs activities including harvesting, extraction and purification, packaging, food and beverage processing, and laboratory testing services. For pharmaceuticals and biotechnology, areas of focus include drug discovery and development, diverse delivery methods (e.g., pills, soft gels, tinctures), biosynthetically derived cannabinoids and other molecules, medical devices (e.g., inhalers), and laboratory equipment. Consumer product interests extend to edibles, beverages, inhalables, cosmetics, and accessories for cannabis consumption. In retail and distribution, the firm targets licensed brick-and-mortar stores, pharmacies, online marketplaces, and delivery services. RIV Capital actively pursues investment opportunities on a global scale. While its historical investment amounts have varied from CA$1 million ($0.71 million) to CA$40 million ($28.45 million), typical investments generally fall within the range of CA$5 million ($3.6 million) to CA$10 million ($7.1 million). The firm predominantly seeks to acquire minority stakes and utilizes a variety of investment instruments, such as debt, preferred and common equity, and production-linked royalties. RIV Capital Inc. was established in 2017 and operates from its headquarters in Toronto, Canada.
Führung
- Matthew Jonathon MundyChief Strategy Officer, General Counsel & Corporate Secretary
- Edward James Cirillo LucarelliChief Financial Officer
- Peter HatziioannouCo-Founder & Advisor
- David E. VautrinChief Retail Officer & Interim Chief Executive Officer
- Sean McNultyCo-Founder & Advisor
- CEO
- David E. Vautrin
- Mitarbeitende
- 94
- Hauptsitz
- Toronto, ON, CA
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 20. Sept. 2018
- Website
- investors.getfluent.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.